
Multiple Myeloma- Pipeline Insight, 2024
Description
Multiple Myeloma- Pipeline Insight, 2024
DelveInsight’s, “Multiple Myeloma- Pipeline Insight, 2024” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Multiple Myeloma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Multiple Myeloma: Overview
Multiple myeloma (MM) is a clonal plasma cell proliferative disorder characterized by the abnormal increase of monoclonal immunoglobulins. Unchecked, the excess production of these plasma cells can ultimately lead to specific end-organ damage. Most commonly, this is seen when at least one of the following clinical manifestations are present: hypercalcemia, renal dysfunction, anemia, or bone pain accompanied by lytic lesions.
Symptoms
The specific symptoms, age of onset, and rate of progression of multiple myeloma varies from patient to patient. Some affected individuals will not exhibit any symptoms (asymptomatic). Multiple myeloma may progress to cause life-threatening complications. The most common symptom associated with multiple myeloma is bone pain, usually of the lower back or ribs. Another possible sign of multiple myeloma is an elevated level of calcium in the blood, a condition called hypercalcemia.
Causes
The exact cause of multiple myeloma is not known. Symptoms occur as a result of a process that is initiated by the abnormal multiplication of plasma cells in bone marrow. Scientists suspect there may be a variety of causes that may include environmental factors (e.g., the effects of exposure to radiation), genetic abnormalities, and/or additional factors that may play varying contributing roles. Exposure to dioxin has been associated with an increased risk of myeloma.
Diagnosis
A diagnosis of multiple myeloma is made based upon a thorough clinical evaluation, a detailed patient history, and a variety of specialized tests. Such tests may include removal and microscopic examination of small samples of bone marrow (biopsy or aspiration), blood tests to detect low levels of red and white blood cells, and various x-ray techniques including magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) scanning that may reveal characteristic changes to bones. A test that uses electric currents to sort proteins in the blood or urine (electrophoresis) may be used to detect elevated levels of M-proteins. An immunoglobulin free light chain assay of blood is considered a standard of evaluation.
Treatment
The treatment of multiple myeloma usually involves chemotherapy to reduce the numbers of abnormal plasma cells, drugs to help fight infection (e.g., antibiotics), and medications to reduce pain (analgesic drugs). Additional treatment may include the use of high energy x-rays (radiation therapy) to destroy cancer cells and reduce bone masses that may develop. The use of new biologic drugs may also be recommended. If affected individuals experience involvement of the kidneys, fluids may need to be administered to avoid dehydration. Stem-cell transplantation along with high-dose chemotherapy is regularly used for the treatment of multiple myeloma.
""Multiple Myeloma- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Multiple Myeloma pipeline landscape is provided which includes the disease overview and Multiple Myeloma treatment guidelines. The assessment part of the report embraces, in depth Multiple Myeloma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Multiple Myeloma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Multiple Myeloma R&D. The therapies under development are focused on novel approaches to treat/improve Multiple Myeloma.
This segment of the Multiple Myeloma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Multiple Myeloma Emerging Drugs
- Zevorcabtagene Autoleucel: Carsgen Therapeutics
- Descartes 08: Cartesian Therapeutics
- GC012F: Gracell Biotechnology Shanghai Co., Ltd.
- CID-103: CASI Pharmaceuticals
- STI-1492: Sorrento Therapeutics
Further product details are provided in the report……..
Multiple Myeloma: Therapeutic Assessment
This segment of the report provides insights about the different Multiple Myeloma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Multiple Myeloma
- There are approx. 75+ key companies which are developing the therapies for Multiple Myeloma. The companies which have their Multiple Myeloma drug candidates in the most advanced stage, i.e. Registered include, Carsgen Therapeutics.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Multiple Myeloma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Multiple Myeloma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Multiple Myeloma drugs.
Multiple Myeloma Report Insights
- Multiple Myeloma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Multiple Myeloma drugs?
- How many Multiple Myeloma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Multiple Myeloma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Multiple Myeloma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Multiple Myeloma and their status?
- What are the key designations that have been granted to the emerging drugs?
- CASI Pharmaceuticals
- Carsgen Therapeutics
- Cartesian Therapeutics
- Gracell Biotechnology Shanghai Co., Ltd.
- Sorrento Therapeutics
- TeneoOne
- Karyopharma Therapeutics
- Arcellx
- Poseida Therapeutics
- Ichnos Sciences
- Nerviano Medical Sciences
- Bristol Myers Squib
- Ascentage Pharma
- Ionis Pharmaceuticals
- Chongqing Precision Biotech Co., Ltd.
- CRISPR Therapeutics
- AstraZeneca
- IGM Biosciences
- Novartis
- GlaxoSmithKline
- Innovent Biologics
- Keymed Biociences
- Starton Therapeutics
- Takeda
- Fate Therapeutics
- Gilead Sciences
- Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
- Janssen Pharmaceutical
- Nanjing IASO Biotechnology Co., Ltd.
- GPCR Therapeutics
- Chimerix
- CID-103
- Zevorcabtagene Autoleucel
- Descartes 08
- GC012F
- STI-1492
- TNB-383B
- Selexinor
- CART-ddBCMA
- P-BCMA-ALLO1 CAR-T cells
- ISB 1342
- NMS-03597812
- CC-95266
- APG-2575
- ION251
- C-4-29 Cells
- CTX120
- AZD0305
- IGM-2644
- PHE885
- Belantamab mafodotin
- IBI3003
- CM313
- Lenalidomide
- Modakafusp alfa
- FT576
- Magrolimab
- FHND6091
- Talquetamab
- CT103A
- GPC-100
- ONC201
Table of Contents
230 Pages
- Introduction
- Executive Summary
- Multiple Myeloma: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Multiple Myeloma– DelveInsight’s Analytical Perspective
- Late Stage Products (Registered)
- Comparative Analysis
- Zevorcabtagene Autoleucel: Carsgen Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Descartes 08: Cartesian Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- CID-103: CASI Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Multiple Myeloma Key Companies
- Multiple Myeloma Key Products
- Multiple Myeloma- Unmet Needs
- Multiple Myeloma- Market Drivers and Barriers
- Multiple Myeloma- Future Perspectives and Conclusion
- Multiple Myeloma Analyst Views
- Multiple Myeloma Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.